Company Overview of Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. operates as a research-based pharmaceutical company that discovers, develops, and commercializes pharmaceutical products. It offers olmesartan medoxomil, hydrochlorothiazide, prasugrel, cevimeline HCI, amlodipine, colesevelam HCI, and vemurafenib tablets. The company provides therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma areas. It serves patients, and professional organizations and institutions in the United States and internationally. Daiichi Sankyo, Inc. was formerly known as Sankyo Pharma Inc. and changed its name to Daiichi Sankyo, Inc. in April 2006. The company was founded in 1996 and is based in Parsippany, New...
Two Hilton Court
Parsippany, NJ 07054
Founded in 1996
Key Executives for Daiichi Sankyo, Inc.
Executive Chairman, President, Global Head of Research & Development - Daiichi Sankyo Ltd and Senior Executive Officer of Daiichi Sankyo Ltd
Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co., Ltd. and President of Daiichi Sankyo Co., Ltd.
President of Commercial Operations
Executive Vice President and Head of Global Business Development
Compensation as of Fiscal Year 2015.
Daiichi Sankyo, Inc. Key Developments
Daiichi Sankyo, Inc. Reports Revenue Results for the First Quarter of Fiscal 2016; Revised Revenue Guidance for Fiscal 2016
Jul 31 15
Daiichi Sankyo, Inc. reported revenue results for the first quarter of fiscal 2016. Revenue was JPY 48.0 billion against JPY 41.6 billion last year.
The company revised revenue guidance for fiscal 2016. The company expects revenue of JPY 166.0 billion against previous guidance of JPY 140.0 billion.
AstraZeneca Announces Co-Commercialization Agreement with Daiichi Sankyo, Inc. for MOVANTIK
Mar 19 15
AstraZeneca announced a co-commercialization agreement with Daiichi Sankyo, Inc. for MOVANTIK (naloxegol) in the US, in line with the Company's strategy of delivering value through its own development and commercial capabilities as well as through external collaboration. MOVANTIK is a first-in-class once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Under the terms of the agreement, Daiichi Sankyo Inc. will pay a $200 million up-front fee and subsequent sales-related payments of up to $625 million. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo, Inc. Both companies will be jointly responsible for commercial activities.
Georgia Enters National Settlement with Daiichi Sankyo, Inc. to Resolve Kickback Allegations
Mar 19 15
Georgia Attorney General Sam Olens announced on March 19, 2015, that Georgia has joined the federal government, 48 states and the District of Columbia to reach an agreement with Daiichi Sankyo, Inc. The agreement settles allegations that the company violated the False Claims Act by providing kickbacks to physicians to induce them to prescribe the drugs Azor, Benicar, Tribenzor, and Welchol. Daiichi Sankyo will pay the states and the federal government $39 million in civil damages and penalties. Georgia's share of the settlement is $415,579.02, of which $162,015.12 will be returned directly to the Georgia Department of Community Health. The investigation and ensuing settlement stemmed from a false claims action filed by a former Daiichi Sankyo sales representative in 2010. The whistleblower alleged that between 2004 and 2011, physicians who participated in or claimed to participate in promotional speaker programs received honoraria payments, lavish meals and other remuneration as kickbacks for prescribing the drugs. The settlement agreement reimburses the federal government and the participating states for damages that were assessed in accordance with the amounts that Daiichi Sankyo expended on each speaker program for each fiscal year. Additionally, as part of the settlement, Daiichi Sankyo has agreed to enter into a corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, which obligates Daiichi Sankyo to undertake substantial internal compliance reforms for the next five years.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|